LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Identify practical strategies for confirming diagnosis in a busy primary care clinical setting
• Apply key aspects of available guidelines to inform treatment selection and patient evaluation
• Evaluate new and emerging agents approved for psoriasis, their mechanisms, and efficacy and safety data
• Recognize scenarios in which referral to a specialist for diagnostic or treatment purposes is recommended

FACULTY
Daniel G. Federman, MD, FACP
Professor of Medicine
Yale University School of Medicine
Associate Chief of Medicine
VA Connecticut Healthcare System
West Haven, Connecticut

Steven R. Feldman, MD, PhD
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Barbara Yawn, MD, MSc, MsPH
Adjunct Professor
University of Minnesota
Rochester, Minnesota

ACCREDITED PROVIDER
This activity is provided by the Louisiana Nurse Practitioner Foundation (LNPF) under the sponsorship of the American Association of Nurse Practitioners and in collaboration with The France Foundation.

TARGET AUDIENCE
This activity is intended for primary care physicians, nurse practitioners, and physician assistants.

STATEMENT OF NEED
PCPs face challenges surrounding every aspect of psoriasis care, from diagnosis to management to referral for specialty care. Since PCPs are often responsible for evaluation and management of patients with psoriasis, it is crucial that they are prepared with diagnostic skills, familiar with treatment options and guidelines, and aware of scenarios in which referral for specialist expertise is warranted. Mastery of these skills can in turn contribute to improved care for affected patients, who are often dissatisfied with care.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION
Nurses
This activity is approved for 1.0 contact hour of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 17092829. This activity was planned in accordance with AANP CE Standards and Policies.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosure–Content Creators
The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Daniel Federman
• Dr. Barbara Yawn

The following faculty report that they have relevant financial relationships to disclose:

• Dr. Steven Feldman serves as a consultant for Abbvie, Alvotech, Advance Medical, Caremark, Celgene, Galderma Laboratories, L.P., Gerson Lehrman Group, Guidepoint Global, Janssen, Kikaku, Leo Pharma Inc., Lilly, Merck & Co, Inc., Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, Valeant, and Xenoport. He receives grant support from Abbvie, Celgene, Galderma Laboratories, L.P., Janssen, Lilly, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Sanofi, and Taro. Dr. Feldman is a speaker for Abbvie, Celgene, Janssen, Leo Pharma, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Sanofi, Taro, and Valeant. He receives royalties from Informa, UpToDate, and Xlibris. He is a stock holder for Causa Technologies and Medical Quality Enhancement Corporation.

DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Novartis.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2017 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.